Not on air · 2 of 3 networks checked
TECENTRIQ® (atezolizumab) ads
- tecentriq-hcp.com
- Pharmaceutical Manufacturing
- 4 employees
TECENTRIQ® (atezolizumab)’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 98. Watch TECENTRIQ® (atezolizumab) on any plan to get each new one in your feed.
Watchlist included in every plan
What TECENTRIQ® (atezolizumab) runs
- Single image · LinkedIn
- 1
- Video · LinkedIn
- 5
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksNov 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 8 Nov 2026 | See all 98 ads → | ||
| Meta | Not checked | — | |||
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 19 Oct 2026 | Collect them with the API → |
TECENTRIQ® (atezolizumab) has no live LinkedIn ads. We recorded no Google ads on 19 Oct 2026.
Latest ads
- LINKEDIN · VIDEORecorded 16 Oct 2026
Meet Mike, a patient who has unresectable HCC with high-risk disease characteristics. Do you see patients like Mike who might be eligible for treatment with TECENTRIQ + Avastin® (bevacizumab)? Please see full PI: bit.ly/TCQPI
- LINKEDIN · VIDEORecorded 16 Oct 2026
Meet Shonda, a patient who has metastatic HCC and a history of varices. Do you see patients like Shonda who might be eligible for treatment with TECENTRIQ + Avastin® (bevacizumab)? Please see full PI: bit.ly/TCQPI
- LINKEDIN · VIDEORecorded 16 Oct 2026
Meet Mateo, a patient who has unresectable HCC with progression after locoregional therapy. Do you see patients like Mateo who might be eligible for treatment with TECENTRIQ + Avastin® (bevacizumab)? Please see full PI: bit.ly/TCQPI
- LINKEDIN · IMAGERecorded 16 Oct 2026
Now approved! Discover the new IMforte regimen. Please see full PI: bit.ly/TCQPI #IMforteregimen
- LINKEDIN · VIDEORecorded 16 Oct 2026
See 👀 pivotal data in 1L unresectable or mHCC that may benefit patients in treatment. Please see full PI: bit.ly/TCQPI
- LINKEDIN · VIDEORecorded 16 Oct 2026
💫 It’s up to you. Explore a treatment with clear data and administration options and decide what fits best for your patient. In PD-L1+ adjuvant NSCLC treatment, you can choose from subcutaneous or IV atezolizumab administration options. Plus, TECENTRIQ has pivotal and exploratory survival data with over 5 years of follow-up. Bring clarity to your treatment decisions. Choose atezolizumab. Please see SC PI: bit.ly/SQPI and IV PI: bit.ly/TCQPI
6 of 98 adsSign up to see every TECENTRIQ® (atezolizumab) ad, filter by format and date, and get alerts on new ones.
See all 98 adsQuestions about TECENTRIQ® (atezolizumab)’s ads
Is TECENTRIQ® (atezolizumab) running LinkedIn ads?
We recorded no live LinkedIn ads for TECENTRIQ® (atezolizumab) on 9 Nov 2026.
How many LinkedIn ads has TECENTRIQ® (atezolizumab) run?
LinkedIn’s ad library lists 98 ads for TECENTRIQ® (atezolizumab). We recorded 98 LinkedIn ads for TECENTRIQ® (atezolizumab), first recorded on 16 Oct 2026 and last recorded on 28 Oct 2026.
Does TECENTRIQ® (atezolizumab) run Google ads?
We recorded no Google ads for the domain tecentriq-hcp.com on 19 Oct 2026.
Which ad formats does TECENTRIQ® (atezolizumab) use?
The 6 LinkedIn ads on this page include 1 image ad and 5 video ads.
Watch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.